Welcome to our dedicated page for Nuvectis Pharma news (Ticker: NVCT), a resource for investors and traders seeking the latest updates and insights on Nuvectis Pharma stock.
Nuvectis Pharma, Inc. reports developments as a clinical-stage biopharmaceutical company focused on precision medicines for serious oncology indications. Company news centers on NXP900, an oral small-molecule inhibitor of the SRC Family of Kinases, including SRC and YES1, and on clinical and preclinical work in genetically or molecularly defined cancer settings.
Recurring updates include financial results, business highlights, clinical program progress, AACR and other oncology conference presentations, pharmacokinetic and pharmacodynamic findings, drug-drug interaction data, and combination-therapy research in non-small cell lung cancer and other advanced solid tumors. News also covers capital resources and financing activity tied to development operations.
Nuvectis Pharma, Inc. (Nasdaq: NVCT) has announced the pricing of its initial public offering (IPO) of 3,200,000 shares at $5.00 each, aiming for gross proceeds of $16 million. The underwriter, H.C. Wainwright & Co., has an option to purchase an additional 480,000 shares. Proceeds will be allocated to the Phase 1/2 development of NXP800, IND-enabling studies for NXP900, and other corporate needs. Trading on the Nasdaq begins today with the offering expected to close on February 8, 2022, subject to customary closing conditions.